Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $44.92 USD
Change Today +0.90 / 2.04%
Volume 506.8K
INSY On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

insys therapeutics inc (INSY) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/31/15 - $45.90
52 Week Low
08/1/14 - $11.26
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

insys therapeutics inc (INSY) Related Businessweek News

No Related Businessweek News Found

insys therapeutics inc (INSY) Details

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients; and Dronabinol SG Capsule, a dronabinol soft gelatin capsule that is generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Its products candidates also include Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. The company is headquartered in Chandler, Arizona.

382 Employees
Last Reported Date: 03/3/15

insys therapeutics inc (INSY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $889.2K
Chief Financial Officer
Total Annual Compensation: $383.0K
General Counsel and Corporate Secretary
Total Annual Compensation: $315.5K
Compensation as of Fiscal Year 2014.

insys therapeutics inc (INSY) Key Developments

Insys Therapeutics Submits New Drug Application for Dronabinol Oral Solution

Insys Therapeutics announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for its proprietary Dronabinol Oral Solution for anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol Oral Solution is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a synthetic version of tetrahydrocannabinol. The company announced that it expects its new, DEA-inspected facility in Round Rock, Texas, will enable it to manufacture ample quantities of its pharmaceutical-grade cannabinoid products, including Dronabinol Oral Solution and pharmaceutical cannabidiol, for its research needs and to meet anticipated demand for its pipeline products, if approved. In October 2014, the company received a Refusal to File letter for its previously-submitted NDA for Dronabinol Oral Solution because that submission included an inadequate or incomplete pediatric study plan to conduct studies to assess the safety and effectiveness of Dronabinol Oral Solution in pediatric patients. The company now expects the current NDA contains all information required to permit a substantive review by the FDA, and intends to continue to work closely with the FDA throughout the review process.

INSYS Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

INSYS Therapeutics, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, net revenue of the company increased to $70,770,000 versus $41,636,000 a year ago. Income from operations was $11,631,000 against $12,669,000 a year ago. Income before income taxes was $11,756,000 against $12,688,000 a year ago. Net income was $8,023,000 or $0.21 per diluted share compared to $7,658,000 or $0.21 per diluted share per diluted share a year ago. Adjusted income before income taxes was $23,477,000 against $15,143,000 reported last year. Adjusted net income per diluted share was $0.63 against $0.41 a year ago. EBITDA was $12,806,000 against $13,205,000 and adjusted EBITDA was $24,527,000 against $15,660,000 reported last year.

INSYS Therapeutics, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 09:00 AM

INSYS Therapeutics, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 09:00 AM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States. Speakers: Darryl S. Baker, Chief Financial Officer, Michael L. Babich, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INSY:US $44.92 USD +0.90

INSY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $8.16 USD +0.31
Array BioPharma Inc $5.81 USD +0.06
Depomed Inc $31.50 USD +0.97
Seattle Genetics Inc $47.87 USD +0.53
Spectrum Pharmaceuticals Inc $6.92 USD +0.145
View Industry Companies

Industry Analysis


Industry Average

Valuation INSY Industry Range
Price/Earnings 86.2x
Price/Sales 12.7x
Price/Book 17.4x
Price/Cash Flow 83.7x
TEV/Sales 12.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSYS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at